Research programme: H5N1 avian influenza vaccine - Takeda/University of Wisconsin
Latest Information Update: 23 Jul 2014
At a glance
- Originator InViragen LLC; University of Wisconsin-Madison
- Developer Takeda Pharmaceuticals USA; University of Wisconsin-Madison
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H5N1 subtype